var data={"title":"Treprostinil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Treprostinil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=treprostinil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Treprostinil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230363\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Orenitram;</li>\n      <li>Remodulin;</li>\n      <li>Tyvaso;</li>\n      <li>Tyvaso Refill;</li>\n      <li>Tyvaso Starter</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000889\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Remodulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230380\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Prostacyclin;</li>\n      <li>\n        Prostaglandin;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230365\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pulmonary arterial hypertension (PAH):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inhalation: <b>Note:</b> Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil and care for the inhalation system and accessories required for administration. Immediate access to a back-up inhalation device, accessories, and medication is essential to prevent treatment interruptions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial: 18 mcg (or 3 inhalations) every 4 hours 4 times/day; if 3 inhalations are not tolerated, reduce to 1 to 2 inhalations, then increase to 3 inhalations as tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: If tolerated, increase dose by an additional 3 inhalations at approximately 1- to 2-week intervals; target dose and maximum dose: 54 mcg (or 9 inhalations) 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Initial: 0.25 mg every 12 hours or 0.125 mg every 8 hours; may increase dose  in increments of 0.25 mg or 0.5 mg every 12 hours or 0.125 mg every 8 hours every 3 to 4 days as tolerated to achieve optimal clinical response. If  dose increments are not tolerated, consider slower titration. Maximum dose is determined by tolerability. If intolerable effects occur, decrease dose in increments of 0.25 mg; avoid abrupt discontinuation. Upon discontinuation, reduce the dose in increments of 0.5 mg to 1 mg daily. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Conversion from injection to oral dosing:</i> Decrease the dose of parenteral treprostinil up to 30 ng/kg/minute per day while simultaneously increasing the dose of oral treprostinil up to 2 mg 3 times daily as tolerated. To estimate a comparable total daily dose of oral treprostinil, use the following equation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Treprostinil oral total daily dose (mg) = Parenteral treprostinil dose (ng/kg/minute) x weight (kg) x 0.0072</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Missed doses:</i> If a dose is missed, take the missed dose as soon as possible. If &ge;2 doses are missed, restart at a lower dose and retitrate. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosage adjustment for concurrent use in patients receiving strong CYP2C8 inhibitors (gemfibrozil):</i> Initiate a starting dose of 0.125 mg every 12 hours; increase in increments of 0.125 mg every 12 hours every 3 to 4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Planned short-term treatment interruption:</i> If patients are unable to continue oral treatment, a temporary infusion of parenteral treprostinil may be considered. Multiply the oral total daily dose (mg) by 139 and divide by patient&rsquo;s weight (kg) to calculate the total daily dose of parenteral treprostinil (ng/kg/minute). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SubQ (preferred) or IV infusion: <b>Note:</b> Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil and care for the infusion system outside of inpatient setting. Immediate access to a back-up pump, infusion sets, and medication is essential to prevent treatment interruptions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>New to prostacyclin therapy:</i> Initial: 1.25 ng/kg/minute; if dose cannot be tolerated due to systemic effects, reduce to 0.625 ng/kg/minute. Increase dose in increments of 1.25 ng/kg/minute per week for first 4 weeks, followed by increments of 2.5 ng/kg/minute per week for remainder of therapy. Limited experience with doses &gt;40 ng/kg/minute. <b>Note:</b> Dose must be carefully and individually titrated (symptom improvement with minimal adverse effects). Avoid abrupt withdrawal. If infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Transitioning from epoprostenol (see table):</i>\n      <b> Note:</b> Transition should occur in a hospital setting to follow response (eg, walking distance, sign/symptoms of disease progression). May take 24 to 48 hours to transition. Transition is accomplished by initiating the infusion of treprostinil, and increasing it while simultaneously reducing the dose of intravenous epoprostenol. During transition, increases in PAH symptoms should be first treated with an increase in treprostinil dose. Occurrence of prostacyclin associated side effects should be treated by decreasing the dose of epoprostenol.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Transitioning From IV Epoprostenol to SubQ (Preferred) or IV Treprostinil</caption>\n      <col align=\"center\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Step</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Epoprostenol Dose</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Treprostinil Dose</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Maintain current dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Initiate at 10% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Decrease to 80% initial dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Increase to 30% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Decrease to 60% initial dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Increase to 50% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Decrease to 40% initial dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Increase to 70% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Decrease to 20% initial dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Increase to 90% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Decrease to 5% initial dose</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Increase to 110% initial epoprostenol dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Discontinue epoprostenol</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Maintain current dose plus additional 5% to 10% as needed</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230374\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ; IV infusion: Limited experience in patients &le;16 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062238\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Limited experience in patients &ge;65 years; use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230366\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation, SubQ infusion, IV infusion: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Use with caution and titrate slowly. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Treprostinil is not removed by dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230367\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, hepatic impairment increases systemic exposure to treprostinil. Use with caution and titrate slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ infusion, IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: Initial: 0.625 ng/kg/minute (ideal body weight). Use with caution and titrate slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Use with caution and titrate slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): Initial: 0.125 mg every 12 hours; increase in increments of 0.125 mg every 12 hours every 3 to 4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (Child-Pugh class B): Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): Use is contraindicated by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230343\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tyvaso: 0.6 mg/mL (2.9 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tyvaso Refill: 0.6 mg/mL (2.9 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tyvaso Starter: 0.6 mg/mL (2.9 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Remodulin: 1 mg/mL (20 mL); 2.5 mg/mL (20 mL); 5 mg/mL (20 mL); 10 mg/mL (20 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orenitram: 0.125 mg, 0.25 mg, 1 mg, 2.5 mg, 5 mg [contains fd&amp;c blue #2 (indigotine)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230331\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230345\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Avoid treatment interruptions or rapid large dosage reductions with use of inhalation, IV, or SubQ formulations. Immediate access to medication, a back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Inhalation: Do not mix with other medications. For inhalation only via the Tyvaso Inhalation System. Prior to the first treatment session of each day, transfer the entire contents of one ampule into the medicine chamber; one ampule contains sufficient volume of medication for all 4 treatment sessions in a single day. Between each session, the device should be capped and stored upright with the remaining medication inside. At the end of each day, the medicine chamber and any remaining medication must be discarded. Avoid contact of solution with eyes or skin; wash hands after handling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV infusion: IV use is recommended when SubQ infusion is not tolerated or when the benefit outweighs the potential risks of an indwelling central venous catheter. Solution must be diluted in SWFI, NS, Remodulin sterile diluent, or Flolan sterile diluent prior to use and administered by continuous infusion using a central indwelling catheter and infusion pump. The ambulatory infusion pump should be small and lightweight; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have &plusmn; 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Peripheral infusion may be used temporarily until central line is established. Infusion sets with an in-line 0.22 or 0.2 micron filter should be used for central and peripheral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food (minimum of 250 calories containing 30% to 50% fat) (Lim 2013; Pugliese 2016). Swallow tablets whole; do not crush, split or chew; use only intact tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ infusion (preferred): Administer undiluted via continuous SubQ infusion using an appropriately designed infusion pump. The ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in ~0.002 mL/hour increments; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have &plusmn; 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Proactively manage infusion-site reactions based on individual patient needs and by combining multiple strategies, including improved dosing strategies (eg, more rapid dose escalation), appropriate site selection, less frequent infusion site changes (eg, every 2 to 5 weeks [Skoro-Sajer 2007]), and analgesic care (pharmacologic and nonpharmacologic) when pain occurs. Rotate infusion site when patient experiences continued site pain, itching, erythema, drainage, or bleeding; decreased site pain and need for site changes or discontinuation due to site pain may be reduced in patients who are managed proactively in this manner (Mathier 2010; Skoro-Sajer 2008; White 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230344\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Pulmonary arterial hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA class II-IV symptoms to decrease exercise-associated symptoms; to diminish clinical deterioration when transitioning from epoprostenol (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Inhalation: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA class III symptoms to improve exercise ability. <b>Note:</b> Nearly all controlled clinical trial experience has been with concomitant bosentan or sildenafil.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Oral: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional class II-III symptoms to improve exercise capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230336\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (oral, oral inhalation: 15%), vasodilatation (subQ: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Infusion-site pain (subQ: 85%, severe: 39%), headache (oral: 63%; oral inhalation: 41%; subQ: 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (subQ: 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (oral, oral inhalation: 25% to 30%), nausea (19% to 30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (subQ: 83%, severe: 38%, including erythema, induration, skin rash)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (oral: 14%), jaw pain (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (inhalation: 54%), pharyngolaryngeal pain (inhalation: &le;25%), throat irritation (inhalation: &le;25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (subQ: 9%), syncope (inhalation: 6%), hypotension (subQ: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (oral: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress (oral: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (oral, subQ), pain (subQ), paresthesia (subQ)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma (subQ)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (oral, oral inhalation), swelling of extremities (arm; subQ)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (inhalation; long-term therapy), hemoptysis (inhalation; long-term therapy), nasal discomfort (inhalation; long-term therapy), pneumonia (oral inhalation; long-term therapy), sore throat (oral inhalation), wheezing (inhalation; long-term therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, arthralgia, catheter infection (central venous; positive blood culture), cellulitis, dyspepsia, maculopapular rash, ostealgia, papular rash, pruritus, thrombocytopenia, thrombophlebitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230348\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection/inhalation: There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to treprostinil or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for prostaglandins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230334\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: May  inhibit platelet aggregation and increases the risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: May produce symptomatic hypotension; use with caution in patients with low systemic arterial blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rebound pulmonary hypertension: Abrupt withdrawal/large dosage reductions may worsen symptoms of PAH. If a SubQ or IV infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration. Regardless of administration route (inhalation, IV, oral, SubQ), treatment interruptions should be avoided. Immediate access to medication, back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- IV/SubQ:  Dose reduction is recommended for the initial dose in patients with mild to moderate hepatic insufficiency; titrate dose slowly in patients with hepatic insufficiency; has not been studied in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Oral: Dose reduction is recommended for patients with mild hepatic impairment. Avoid use in patients with moderate impairment; use is contraindicated in patients with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Inhalation, IV, SubQ: Has not been studied in renal impairment; use with caution in patients with renal impairment. Titrate dose slowly in patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Inhalation: Safety and efficacy have not been established in patients with underlying pulmonary disease (eg, asthma, COPD). Patients with acute pulmonary infections should be monitored closely for exacerbation or reduced efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ethanol use: Tablets should not be administered with ethanol because the release of treprostinil from the tablet may occur at a faster rate than intended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablet: Tablet shell does not dissolve and is eliminated in the feces as an insoluble shell; in patients with diverticulosis, tablet can lodge in a diverticulum.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Chronic continuous IV infusion of treprostinil via a chronic indwelling central venous catheter has been associated with serious blood stream infections. This method of administration should be reserved for patients who are intolerant of the SubQ route or in whom the benefit outweighs the potential risks. Clinicians should routinely review with patient the importance of infection control practices for the management of a central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Treprostinil injection should only be used by clinicians experienced in the treatment of PAH. Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil, either as an IV/SubQ infusion or inhalation, and care for the infusion system/inhalation device. Initiation of infusion must occur in a setting where adequate personnel and equipment necessary for hemodynamic monitoring and emergency treatment are available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300164\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C8 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230338\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10207&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the absorption of Treprostinil. Specifically, a more rapid and/or complete absorption of Treprostinil from extended-release tablets is possible. Management: Avoid administration of treprostinil extended release tablets with alcohol, and advise patients to avoid this combination.  No such interaction is expected with other treprostinil formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Treprostinil. Management: Reduce the initial treprostinil extended release tablet dose to 0.125 mg twice daily, titrating by 0.125 mg twice daily every 3 to 4 days.  No preemptive dose adjustment is recommended for other treprostinil products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230340\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (product specific)  (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230350\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17918018\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if treprostinil is excreted in breast milk. The manufacturers of the injection recommend that caution be exercised when administering treprostinil to nursing women. The manufacturer of the oral product recommends that a decision be made whether to discontinue nursing or to discontinue the drug. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230341\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BP, dyspnea, fatigue, activity tolerance, symptoms of excessive dose (eg, headache, nausea, vomiting)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230333\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Treprostinil is a direct vasodilator of both pulmonary and systemic arterial vascular beds; also inhibits platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230347\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Affected by food; AUC<sub>inf</sub> increased by 49% when administered following a high-fat, high-calorie meal compared to fasting conditions. Relative bioavailability following oral administration of 1 mg is not significantly altered by meals ranging from 250 to 500 calories.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SubQ: Rapidly and completely</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 14 L/70 kg ideal body weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 91% to 96% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (primarily by CYP2C8); forms 5 inactive metabolites (HU1-HU5)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Inhalation: 64% to 72% (dose-dependent); SubQ: 100%; Oral: ~17%  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urine (79%; 4% as unchanged drug, 64% as metabolites); feces (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: urine (0.19% as unchanged drug); feces (1.13% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324023\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Remodulin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (20 mL): $1,474.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (20 mL): $3,685.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (20 mL): $7,370.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $14,740.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tyvaso Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/mL (2.9 mL): $675.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tyvaso Refill Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/mL (2.9 mL): $675.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tyvaso Starter Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/mL (2.9 mL): $1,221.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Orenitram Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (10): $61.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (10): $122.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (10): $490.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (10): $1,227.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (10): $2,454.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301443\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Remodulin (AR, AT, AU, BB, BE, BM, CH, CL, CR, CZ, DE, DK, DO, EE, FI, FR, GR, GT, HN, HU, IL, IS, IT, KR, LT, LU, NI, NL, NO, PA, PL, PT, SE, SI, SK, SV, TW);</li>\n      <li>Treprost (JP);</li>\n      <li>Tyvaso (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Bloodstream Infections Among Patients Treated With Intravenous Epoprostenol or Intravenous Treprostinil for Pulmonary Arterial Hypertension - Seven Sites, United States, 2003-2006,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2007, 56(8):170-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/17332729/pubmed\" target=\"_blank\" id=\"17332729\">17332729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gildea TR, Arroliga AC, and Minai OA, &ldquo;Treatments and Strategies to Optimize the Comprehensive Management of Patients With Pulmonary Arterial Hypertension,&rdquo; <i>Cleve Clin J Med</i>, 2003, 70(Suppl 1):18-27.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gomberg-Maitland M, Tapson VF, Benza RL, et al, &ldquo;Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension,&rdquo; <i>Am J Respir Crit Care Med</i>, 2005, 172(12):1586-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/16151039/pubmed\" target=\"_blank\" id=\"16151039\">16151039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang I, Gomez-Sanchez M, Kneussl M, et al, &ldquo;Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension,&rdquo; <i>Chest</i>, 2006, 129(6):1636-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/16778286/pubmed\" target=\"_blank\" id=\"16778286\">16778286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lim A, Wang-Smith L, Kates J, Laurent A, Kumar P, Laliberte K. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers. <i>J Clin Pharm Ther</i>. 2013;38(6):450-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/23927483/pubmed\" target=\"_blank\" id=\"23927483\">23927483</a>]</span><span class=\"doi\">10.1111/jcpt.12085</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. <i>J Heart Lung Transplant</i>. 2010;29(11):1210-1217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/20855220/pubmed\" target=\"_blank\" id=\"20855220\">20855220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo; <i>J Am Coll Cardiol</i>, 2009, 53(17):1573&ndash;619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Gaine SP, Barst RJ, et al, &ldquo;Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension,&rdquo; <i>J Cardiovasc Pharmacol</i>, 2003, 41(2):293-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/12548091/pubmed\" target=\"_blank\" id=\"12548091\">12548091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orenitram (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugliese SC, Bull TM. Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension. <i>Integr Blood Press Control</i>. 2016;9:1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/26869810/pubmed\" target=\"_blank\" id=\"26869810\">26869810</a>]</span><span class=\"doi\">10.2147/IBPC.S68230</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remodulin (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remodulin (treprostinil) [product monograph]. Magog, QC, Canada: Unither Biotech; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubenfire M, McLaughlin VV, Allen RP, et al, &ldquo;Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension,&rdquo; <i>Chest</i>, 2007,132(3):757-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/17400684/pubmed\" target=\"_blank\" id=\"17400684\">17400684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. <i>J Thromb Haemost</i>. 2007;5(3):483-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/18698881/pubmed\" target=\"_blank\" id=\"18698881\">18698881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. <i>Clin Pharmacokinet</i>. 2008;47(9):611-618.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/18698881/pubmed\" target=\"_blank\" id=\"18698881\">18698881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyvaso (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White RJ, Levin Y, Wessman K, Heininger A, Frutiger K. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. <i>Pulm Circ</i>. 2013;3(3):611-621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/treprostinil-drug-information/abstract-text/24618545/pubmed\" target=\"_blank\" id=\"24618545\">24618545</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10207 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F230363\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3000889\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F230380\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F230365\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F230374\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062238\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F230366\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F230367\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F230343\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F230331\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F230345\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F230344\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F230336\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F230348\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F230334\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300164\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F230338\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F230340\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F230350\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17918018\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F230341\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F230333\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F230347\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324023\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301443\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10207|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=treprostinil-patient-drug-information\" class=\"drug drug_patient\">Treprostinil: Patient drug information</a></li></ul></div></div>","javascript":null}